Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741234 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
A Phase 1 study, sponsored by S*BIO.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00741234 is a Phase 1 study that has completed, run by S*BIO. The registered enrollment target is 85 participants.
The verdict
NCT00741234, a Phase 1 study, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.
Interventions
- DRUG Azacitidine
- DRUG SB939
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741234
The ClinicalTrials.gov registry entry for NCT00741234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is S*BIO, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00741234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741234 about?
NCT00741234 is a clinical study titled "A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine". This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with adv...
What is the current status of trial NCT00741234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2007-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00741234?
The interventions under investigation include: Azacitidine (DRUG), SB939 (DRUG).
Who is sponsoring clinical trial NCT00741234?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.